Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) AI-Powered Stock Analysis
See how Akums Drugs & Pharmaceuticals Ltd. scores across key metrics like financial growth, valuation, and market position on the NSE, using AI-driven evaluation.
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) AI-Powered Stock Analysis
See how Akums Drugs & Pharmaceuticals Ltd. scores across key metrics like financial growth, valuation, and market position on the NSE, using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continuously improving this model to increase accuracy and performance.Read our Full DisclaimerAkums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) Stock Overall Grade
Akums Drugs & Pharmaceuticals Ltd.'s grade for its NSE listing, based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Grade Breakdown by Metric
See how each financial and market factor contributes to Akums Drugs & Pharmaceuticals Ltd.'s overall NSE stock rating.
Forecast
B+Score
79/100Financial Growth
CScore
40/100Fundamental Growth
BScore
66/100Key Ratios
B+Score
77/100Sector Comparison
BScore
65/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
97/100Analyst Consensus
C+Score
50/100Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) AI-Powered Stock Analysis
On the NSE, AKUMS.NS demonstrates Good performance with an overall Forecast Score of 79/100 (B+), reflecting high confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (66/100, B) highlight its stability, while Key Ratios (77/100, B+) and Sector Comparison (65/100, B) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (97/100, A+), the NSE-listed stock shows competitive strength. Analyst Consensus (50/100, C+) suggests Moderate divergence in outlook.(NSE: AKUMS.NS) Component Analysis Explained
Understand the key factors behind each Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) stock grade, including financials, comparisons, and forecasts.